Cite

    Mease, P., Gladman, D., Gomez-Reino, J., Hall, S., Kavanaugh, A., Lespessailles, E., Schett, G., Paris, M., Teng, L., & Wollenhaupt, J. (n.d.). aB0785 Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 patients with psoriatic arthritis in 3 large, phase iii, long-term studies. Annals of the rheumatic diseases, 76, 1331–1332. http://access.bl.uk/ark:/81055/vdc_100135164346.0x000061